research use only
Cat.No.S8670
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease Tyrosinase DPP HIV Protease |
|---|---|
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|
In vitro |
Water : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1042.14 | Formula | C49H71N9O16 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1702967-37-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O | ||
| Targets/IC50/Ki |
PSMA
(Cell-free assay) 0.37 nM(Ki)
|
|---|---|
| In vitro |
PSMA-617 demonstrates high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant Ki = 2.34 ± 2.94 nM on LNCaP; Ki = 0.37 ± 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells are demonstrated. |
| In vivo |
The small-animal PET measurements show high tumor-to-background contrasts as early as 1 h after injection. In vivo distribution reveals specific uptake in LNCaP tumors and in the kidneys 1 h after injection. With regard to therapeutic use, PSMA-617 exhibits a rapid clearance from the kidneys from 113.3 ± 24.4 at 1 h to 2.13 ± 1.36 percentage injected dose per gram at 24 h. The favorable pharmacokinetics of the molecule leads to tumor-to-background ratios of 1,058 (tumor to blood) and 529 (tumor to muscle), respectively,24 h after injection. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06303713 | Not yet recruiting | Prostate Cancer|Metastatic Prostate Cancer|Metastatic Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute|Novartis |
May 2024 | Phase 1 |
| NCT06004661 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals|Novartis |
April 4 2024 | Phase 2 |
| NCT05766371 | Recruiting | Castrate Resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Prostate Cancer|Prostate Carcinoma |
University of California San Francisco|Merck Sharp & Dohme LLC|Prostate Cancer Foundation |
December 15 2023 | Phase 2 |
| NCT05228106 | Recruiting | Solid Cancers |
Centre de recherche du Centre hospitalier universitaire de Sherbrooke |
January 21 2022 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.